Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Leigh Anne Siino joins executive team to accelerate company’s revenue growth. EXTON, PA., June 17, 2024 — Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is proud to announce the appointment of Leigh Anne Siino as Chief Revenue
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently,
As treatment strategies evolve, rheumatologists are refining SLE care with targeted biologics, driving a paradigm shift in lupus management, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. Exton, PA., June 12, 2024 – Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial
Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth. EXTON, PA., June 10, 2024 — Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, is
US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global Insights. EXTON, PA., May 9, 2024 – Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape has
Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME markets, according to Spherix Global Insights. EXTON, PA., May 1, 2024 — In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases,
Data from Spherix Global Insights’ second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan), opportunities for pipeline agents to make an impact remain. EXTON, PA., April 30, 2024 – Over the past several years, glomerular diseases have garnered significant attention from the
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights. The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those
Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to grow its U.S. field force by 30% as it works with Eisai on direct to patient and caregiver omnichannel marketing campaigns. The landmark Alzheimer’s disease drug ambled
Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. The Japanese drugmaker said 2,000 patients in the U.S.
Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results. “Where it is positioned in the label today is after an anti-TNF, meaning that patients had to have been
After seven months on the market, Regeneron’s Eylea HD is already making strides with ophthalmologists. According to Spherix Global Insights’ research, 81% of ophthalmologists who use Eylea HD to treat wet age-related macular degeneration (AMD) are “highly satisfied,” which tracks closely to the 87% who say the same about Roche
According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious of all interleukins available in PsA. EXTON, PA., April 16, 2024 – In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira (adalimumab,
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals (Nasdaq: MDGL) recently scored a US Food and Drug Administration (FDA) nod for Rezdiffra (resmetirom) as a treatment for MASH, alongside diet and exercise. As the first prescription medicine for a large
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
